ID27884A - Asam-asam indolealkanoat yang disubstitusikan. - Google Patents

Asam-asam indolealkanoat yang disubstitusikan.

Info

Publication number
ID27884A
ID27884A IDW20002212A ID20002212A ID27884A ID 27884 A ID27884 A ID 27884A ID W20002212 A IDW20002212 A ID W20002212A ID 20002212 A ID20002212 A ID 20002212A ID 27884 A ID27884 A ID 27884A
Authority
ID
Indonesia
Prior art keywords
indolealanic
acids substituted
acids
substituted
indolealanic acids
Prior art date
Application number
IDW20002212A
Other languages
English (en)
Indonesian (id)
Inventor
Michael Lee Jones
David Gunn
John Howard Jones
Michael C Van Zandt
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of ID27884A publication Critical patent/ID27884A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IDW20002212A 1998-03-31 1999-03-31 Asam-asam indolealkanoat yang disubstitusikan. ID27884A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8014398P 1998-03-31 1998-03-31

Publications (1)

Publication Number Publication Date
ID27884A true ID27884A (id) 2001-05-03

Family

ID=22155536

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002212A ID27884A (id) 1998-03-31 1999-03-31 Asam-asam indolealkanoat yang disubstitusikan.

Country Status (29)

Country Link
US (9) US6214991B1 (cs)
EP (1) EP1066283B1 (cs)
JP (2) JP3494990B2 (cs)
KR (1) KR100584650B1 (cs)
CN (1) CN1205207C (cs)
AP (1) AP2000001929A0 (cs)
AT (1) ATE269861T1 (cs)
AU (1) AU774929B2 (cs)
BG (1) BG65446B1 (cs)
BR (1) BR9909358A (cs)
CA (1) CA2383983C (cs)
CZ (1) CZ300706B6 (cs)
DE (1) DE69918278T2 (cs)
EE (1) EE200000573A (cs)
ES (1) ES2224632T3 (cs)
HU (1) HUP0101672A3 (cs)
ID (1) ID27884A (cs)
IL (2) IL138711A0 (cs)
MX (1) MXPA02003122A (cs)
NO (1) NO20004900L (cs)
NZ (1) NZ507172A (cs)
OA (1) OA11622A (cs)
PL (1) PL201645B1 (cs)
SK (1) SK7522001A3 (cs)
TR (1) TR200002869T2 (cs)
TW (1) TWI243163B (cs)
WO (1) WO1999050268A2 (cs)
YU (1) YU59600A (cs)
ZA (1) ZA200005577B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269861T1 (de) 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU5960300A (en) * 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20020012630A1 (en) * 2000-05-09 2002-01-31 James Nolan Methods for testing compounds useful in treating diabetic complications
JP2004517851A (ja) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1465629B1 (en) 2002-01-18 2007-03-14 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
CA2395871A1 (en) * 2002-07-26 2004-01-26 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivatives and formulations containing same for use in treatment of diabetic complications
US20060100255A1 (en) * 2002-07-26 2006-05-11 Van Zandt Michael C Substituted indolealkanoic acids derivative and formulations containing same for use in the treatment of diabetic complications
PT1537078E (pt) * 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
ES2266907T3 (es) 2002-12-10 2007-03-01 Wyeth Derivados sustituidos del acido 3-carbonil-indol-1-il-acetico como inhibidor del activador del plasminogeno-1 (pal-1).
JP2006510673A (ja) 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体
DK1569899T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
BR0316584A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004098498A2 (en) * 2003-04-28 2004-11-18 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
KR20060006953A (ko) * 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
ZA200600424B (en) * 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
EP1805136A1 (en) * 2004-10-28 2007-07-11 The Institutes for Pharmaceutical Discovery, LLC Substituted phenylalkanoic acids
HRP20070342A2 (hr) * 2005-01-14 2007-10-31 Genelabs Technologies Derivati indola za liječenje virusnih infekcija
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20080051384A1 (en) * 2006-07-14 2008-02-28 Genelabs Technologies, Inc. Antiviral agents
KR20090042808A (ko) 2006-07-22 2009-04-30 옥사겐 리미티드 씨알티에이치2 길항제 활성을 갖는 화합물
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
EP2265581A1 (en) * 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
GB2457040A (en) * 2008-01-30 2009-08-05 Oxagen Ltd 1-Acetic acid indole derivatives with PGD2 activity
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
ES2613700T3 (es) * 2010-07-16 2017-05-25 The Trustees Of Columbia University In The City Of New York Inhibidores de la aldosa reductasa y usos de los mismos
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CA3025081A1 (en) 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Substituted 3,4-dihydrothieno [3,4-d]pyridazine compounds and use thereof as aldose reductase inhibitors
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
US11530186B2 (en) 2018-03-29 2022-12-20 H. Lee Moffitt Cancer Center and Research Center Institute, Inc. Inhibitors for the β-catenin / T-cell factor protein-protein interaction
BR112021021939A2 (pt) 2019-05-07 2022-02-22 Ucl Business Ltd Tratamento e detecção de neuropatias herdadas e distúrbios associados

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
ES2032749T3 (es) * 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
WO1993012786A1 (en) * 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4960785A (en) 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
EP0427860A1 (en) 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
GB9011335D0 (en) * 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
JPH0641071A (ja) * 1991-09-06 1994-02-15 Taisho Pharmaceut Co Ltd インドール酢酸エステル誘導体
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5391551A (en) 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9409583D0 (en) 1994-05-13 1994-07-06 Pfizer Ltd Indoles
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) * 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
ATE269861T1 (de) 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
DE69918278T2 (de) 2005-07-14
US6426344B2 (en) 2002-07-30
KR20010042330A (ko) 2001-05-25
KR100584650B1 (ko) 2006-05-30
WO1999050268A3 (en) 1999-12-16
NO20004900D0 (no) 2000-09-29
BG65446B1 (bg) 2008-08-29
US7304079B2 (en) 2007-12-04
ATE269861T1 (de) 2004-07-15
US6730794B2 (en) 2004-05-04
MXPA02003122A (es) 2004-04-21
US20040235933A1 (en) 2004-11-25
CN1296485A (zh) 2001-05-23
CA2383983C (en) 2009-09-29
US7105514B2 (en) 2006-09-12
BG104819A (en) 2001-05-31
US20070093530A1 (en) 2007-04-26
HUP0101672A3 (en) 2002-05-28
US6214991B1 (en) 2001-04-10
US20100137301A1 (en) 2010-06-03
US20030018053A1 (en) 2003-01-23
US20080214540A1 (en) 2008-09-04
JP2002509931A (ja) 2002-04-02
OA11622A (en) 2004-09-16
US20120270912A1 (en) 2012-10-25
US7659269B2 (en) 2010-02-09
TWI243163B (en) 2005-11-11
DE69918278D1 (de) 2004-07-29
CN1205207C (zh) 2005-06-08
NZ507172A (en) 2003-10-31
CA2383983A1 (en) 1999-10-07
EP1066283A2 (en) 2001-01-10
YU59600A (sh) 2002-12-10
US8163932B2 (en) 2012-04-24
EE200000573A (et) 2002-04-15
IL138711A (en) 2006-09-05
HUP0101672A2 (hu) 2002-04-29
JP2003155274A (ja) 2003-05-27
AP2000001929A0 (en) 2000-09-30
AU3459599A (en) 1999-10-18
JP3494990B2 (ja) 2004-02-09
TR200002869T2 (tr) 2000-12-21
CZ300706B6 (cs) 2009-07-22
BR9909358A (pt) 2000-12-12
WO1999050268A2 (en) 1999-10-07
ZA200005577B (en) 2002-02-11
US20010016661A1 (en) 2001-08-23
CZ20003607A3 (cs) 2001-03-14
PL201645B1 (pl) 2009-04-30
EP1066283B1 (en) 2004-06-23
PL348244A1 (en) 2002-05-20
ES2224632T3 (es) 2005-03-01
SK7522001A3 (en) 2002-02-05
US20100324039A1 (en) 2010-12-23
AU774929B2 (en) 2004-07-15
IL138711A0 (en) 2001-10-31
NO20004900L (no) 2000-10-17

Similar Documents

Publication Publication Date Title
ID27884A (id) Asam-asam indolealkanoat yang disubstitusikan.
TR199800818A3 (tr) Ikame edilmis diaminokarbonik asitler.
CU23049A3 (es) Dihidropirimidinas.
IT1312540B1 (it) Composto.
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
ID23761A (id) Trisiklik tersubstitusi
DE69919255D1 (de) Graviervorrichtung
ID23219A (id) Trisiklik tersubstitusi
FI980759A0 (fi) Taetningskonstruktion foer suglaodan i en sugvals
DE59911610D1 (de) Substituierte benzoylcyclohexandione
ID29823A (id) Mengirimkan nomor yang diputar
DE59912532D1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
NO980270L (no) Trekkanordning
TR199901284A3 (tr) Ester bilesimleri.
ES1036909Y (es) Pupitre infantil.
FI980743A0 (fi) Gap-valsformare i en pappersmaskin
ES1039261Y (es) Estuche perfeccionado.
ES1041028Y (es) Formulario de correspondencia.
ES1037395Y (es) Tendedero antilluvia.
ES1042117Y (es) Mesa-sombrilla.
ES1040731Y (es) Gafa.
ES1040589Y (es) Expositor-dispensador.
ES1040633Y (es) Escalifono.
ES1040343Y (es) Carrito portafregona.